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Rajesh Raju†, Aswathy Mary Paul†, Vivekanand Asokachandran, Bijesh George, Lekshmi Radhamony,
Meena Vinaykumar, Reshmi Girijadevi* and Madhavan Radhakrishna PillaiClustering the transcriptomic profile of 587 triple-negative
breast cancer (TNBC) cases extracted from 21 breast can-
cer microarray datasets relying on the lack of transcript-
level expression of estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor recep-
tor 2 (Her2), Lehmann and colleagues have categorized
the TNBCs into seven subgroups [1]. From more than
1,000 clinical samples that were characterized as TNBCs
by immunohistochemistry, we report the first com-
pendium of molecular expression-level alterations as
a value-added resource for extended research. This
open-access manually curated resource, the Triple
Negative Breast Cancer Database (TNBCDb) [2], cur-
rently hosts 144 microRNA, 2,696 mRNA, 106 protein
and 13 post-translational modification alterations in
TNBC tissues.
The TNBC tissues are categorized into lymph node-
positive, lymph node-negative and lymph node meta-
static tissues, or otherwise as TNBC-not specified.
TNBCDb hosts experimentally reported alterations in
these tissues compared with ER+, ER+PR+, Her2+, ER+PR
+Her2−, ER−PR−Her2+, luminal A, luminal B and non-
TNBC (if not specified) or matched adjacent normal,
unmatched normal breast or parenchyma tissues as
analyzed. The ethnicity/origin as provided by the au-
thors/deduced, the frequency of observation of the
molecular alterations in terms of the number of pa-
tient samples analyzed per study, fold values of* Correspondence: reshmi@rgcb.res.in
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ence to corresponding research articles are provided
for the curated records.
TNBCDb also hosts the comparative molecular profile
of 39 TNBC cell lines compared among themselves as
well as with 55 non-TNBC cell lines as a tool for selec-
tion of appropriate cell lines for specific studies on the
basis of their molecular background. Effective visualization
of genes differentially regulated in TNBC tissues and cell
lines and, further, the signaling pathways [3,4], biological
processes, molecular functions, cellular localization [5],
protein–protein interactions [6], microRNA targets and
RNA-level co-expressed genes [7] that are associated with
each type of molecule, is enhanced through unique fea-
tures designated the ‘TNBCDb viewer’ and the ‘Network
viewer’ (Figure 1).
Considering the heterogeneity of breast cancers, we
believe the TNBCDb will serve as a platform for selec-
tion of therapeutically relevant molecular entities from
the tissue and cell line information and also for the
selection of appropriate cell lines for evaluation of thera-
peutic targets in the direction of personalized therapy.
We request suggestions from the scientific community
to improve and keep this resource up to date with more
information/clinical parameters through an online portal
[9]. We believe that this initiative will help us to maintain
TNBCDb as a global reference, integration and analysis
platform for TNBC.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 (See legend on next page.)
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Figure 1 Navigation through the Triple-Negative Breast Cancer Database. The Triple Negative Breast Cancer Database (TNBCDb) has
features enabled to search molecule types by molecule gene symbol and different accession numbers (Entrez Gene, OMIM, SwissProt and
MiRbase IDs). To help researchers search genes by gene symbol, a ‘find your gene’ feature has been incorporated that allows selection of
molecules from the browse page or helps find the corresponding gene symbols for your molecule. For each of the microRNAs, mRNAs,
proteins or phosphoproteins, their differential regulation in tissues as well as the cell lines is provided as available. The TNBCDb viewer has
been enabled to facilitate visualization of the regulation of molecules in triple-negative breast cancer (TNBC) tissue(s) versus different types of
non-TNBC tissues and for molecules in one TNBC cell line with another TNBC cell line and with different non-TNBC cell lines highlighting their
fold-change values. The network viewer enables the integrated view of the interactions, co-expressions, biological processes, molecular
function, cellular compartments and the biological pathways that are reported to be associated with each of the molecules in TNBCDb.
Further, researchers can also search by tissue type, cell line name, experiment method and PubMed IDs as individual or multiple queries.
The TNBCDb data in the complete form are available for free download [8]. ER, estrogen receptor; Her2, human epidermal growth factor receptor 2;
LN, lymph node; PR, progesterone receptor.
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